Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Heron Therapeutics (NQ: HRTX )

18.16 USD +0.38 (+2.14%)
Official Closing Price Updated: 5:51 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,496,924
Open 17.76
Bid (Size) 17.60 (3)
Ask (Size) 18.25 (10)
Prev. Close 17.78
Today's Range 17.38 - 18.19
52wk Range 12.52 - 22.40
Shares Outstanding 91,396,509
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important... 
From PR Newswire
Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important... 
From PR Newswire

Performance

YTD
-12.36%
-12.36%
1 Month
+18.54%
+18.54%
3 Month
+1.17%
+1.17%
6 Month
+17.92%
+17.92%
1 Year
+20.99%
+20.99%

More News

Read More
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
From PR Newswire
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
From PR Newswire
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
From PR Newswire
Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences
From PR Newswire
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates
From PR Newswire
Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain
From PR Newswire
Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery
From PR Newswire
Notable Wednesday Option Activity: NYMT, HRTX, SCS
Tags Stocks
From Market News Video
Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.